Literature DB >> 26660432

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

Bas J Wouters1, Ruud Delwel1.   

Abstract

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent discoveries have highlighted an additional important role of dysregulated epigenetic mechanisms in the pathogenesis of the disease. In contrast to genetic changes, epigenetic modifications are frequently reversible, which provides opportunities for targeted treatment using specific inhibitors. In this review, we will provide an overview of the current state of epigenetics and epigenetic therapy in AML and will describe perspectives on how to identify promising new approaches for epigenetic targeted treatment.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26660432     DOI: 10.1182/blood-2015-07-604512

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  104 in total

1.  Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Authors:  Mark P Chao; Andrew J Gentles; Susmita Chatterjee; Feng Lan; Andreas Reinisch; M Ryan Corces; Seethu Xavy; Jinfeng Shen; Daniel Haag; Soham Chanda; Rahul Sinha; Rachel M Morganti; Toshinobu Nishimura; Mohamed Ameen; Haodi Wu; Marius Wernig; Joseph C Wu; Ravindra Majeti
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

2.  Acute myeloid leukemia in very old patients.

Authors:  Vladimir Lj Lazarevic; Anders Bredberg; Fryderyk Lorenz; Emma Öhlander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Stefan Deneberg; Åsa Derolf; Martin Höglund; Gunnar Juliusson
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 3.  An epigenetic view of developmental diseases: new targets, new therapies.

Authors:  Pei Xie; Li-Qun Zang; Xue-Kun Li; Qiang Shu
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

Review 4.  Cohesin Mutations in Myeloid Malignancies.

Authors:  Joseph B Fisher; Maureen McNulty; Michael J Burke; John D Crispino; Sridhar Rao
Journal:  Trends Cancer       Date:  2017-04

Review 5.  N6-methyladenine RNA modification and cancers.

Authors:  Xia Wu; Lina Sang; Yuping Gong
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

Review 6.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

7.  Phase I study of AR-42 and decitabine in acute myeloid leukemia.

Authors:  Sophia G Liva; Christopher C Coss; Jiang Wang; William Blum; Rebecca Klisovic; Bhavana Bhatnagar; Katherine Walsh; Susan Geyer; Qiuhong Zhao; Ramiro Garzon; Guido Marcucci; Mitch A Phelps; Alison R Walker
Journal:  Leuk Lymphoma       Date:  2020-02-08

8.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Authors:  Catherine C Smith; Amy Paguirigan; Grace R Jeschke; Kimberly C Lin; Evan Massi; Theodore Tarver; Chen-Shan Chin; Saurabh Asthana; Adam Olshen; Kevin J Travers; Susana Wang; Mark J Levis; Alexander E Perl; Jerald P Radich; Neil P Shah
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

9.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

Authors:  Michael R McKeown; M Ryan Corces; Matthew L Eaton; Chris Fiore; Emily Lee; Jeremy T Lopez; Mei Wei Chen; Darren Smith; Steven M Chan; Julie L Koenig; Kathryn Austgen; Matthew G Guenther; David A Orlando; Jakob Lovén; Christian C Fritz; Ravindra Majeti
Journal:  Cancer Discov       Date:  2017-07-20       Impact factor: 39.397

10.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.